Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update-Reference-Cited by-同舟云学术

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Published:2017-11-20 Issue:2 Volume:103 Page:210-216
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Amstutz Ursula¹,Henricks Linda M.²,Offer Steven M.³,Barbarino Julia⁴,Schellens Jan H.M.²⁵,Swen Jesse J.⁶,Klein Teri E.⁴,McLeod Howard L.⁷,Caudle Kelly E.⁸,Diasio Robert B.³⁹,Schwab Matthias¹⁰¹¹¹²

Affiliation:

1. University Institute of Clinical Chemistry, Inselspital Bern University Hospital; University of Bern; Bern Switzerland

2. Department of Clinical Pharmacology, Division of Medical Oncology and Division of Pharmacology; the Netherlands Cancer Institute; Amsterdam the Netherlands

3. Department of Molecular Pharmacology and Experimental Therapeutics; Mayo Clinic; Rochester Minnesota USA

4. Department of Biomedical Data Science; Stanford University; Stanford California USA

5. Utrecht Institute for Pharmaceutical Sciences; Utrecht University; Utrecht the Netherlands

6. Department of Clinical Pharmacy & Toxicology; Leiden University Medical Center; Leiden the Netherlands

7. DeBartolo Family Personalized Medicine Institute and the Department of Population Sciences; H. Lee Moffitt Cancer Center & Research Institute; Tampa Florida USA

8. Department of Pharmaceutical Sciences; St. Jude Children's Research Hospital; Memphis Tennessee USA

9. Mayo Clinic Cancer Center; Mayo Clinic; Rochester Minnesota USA

10. Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology; Stuttgart Germany

11. Department of Clinical Pharmacology; University Hospital; Tuebingen Germany

12. Department of Pharmacy and Biochemistry; University of Tuebingen; Tuebingen Germany

Funder

National Institutes of Health

Robert Bosch Foundation

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference41 articles.

1. Clinical pharmacology of 5-fluorouracil;Diasio;Clin. Pharmacokinet.,1989

2. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network;Relling;Clin. Pharmacol. Ther.,2011

3. Characterization of the human dihydropyrimidine dehydrogenase gene;Wei;Genomics,1998

4. CPIC CPIC ® Guideline for Fluoropyrimidines and DPYD https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/

5. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity;Kuilenburg;Eur. J. Cancer,1997

Cited by 394 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Scoping Review of Pharmacogenomic Educational Interventions to Improve Knowledge and Confidence;American Journal of Pharmaceutical Education;2024-02

2. Real‐world implementation of DPYD and UGT1A1 pharmacogenetic testing in a community‐based cancer center;Clinical and Translational Science;2024-01-26

3. Lymph node metastatic penile cancer: a challenge in uro-oncology—guideline-conform treatment;Die Urologie;2024-01-25

4. Personalized Chronomodulated 5‐Fluorouracil Treatment: A Physiologically‐Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy;Clinical Pharmacology & Therapeutics;2024-01-24

5. Common dihydropyrimidinase (DPYS) genetic variations do not predict fluoropyrimidine-related chemotherapy toxicity in a Canadian cohort;Pharmacogenetics and Genomics;2024-01-15